Polyplus-transfection granted Roche Glycart a nonexclusive license to use polyethylenimine (PEI) for in vitro transfection research applications. Roche Glycart will become a Polyplus sublicensee and incorporate the reagent into its R&D of antibody-based products.
Polyplus reports that its jetPEI transfection reagent is a linear polyethylenimine derivative, free of components of animal origin, and provides effective and reproducible gene delivery into mammalian cells. It can be used in recombinant protein production as well as virus production in cell lines used for protein expression, such as CHO and HEK293. It achieves high DNA transfection with low cytotoxicity, according to the company.
“We are delighted to sign this license agreement with Roche Glycart AG, an innovative subsidiary of Roche, focused in the research and development of new engineered antibody-based products,” says Mark Bloomfield, CEO of Polyplus-transfection. “PEI-mediated transfection is clearly an essential research tool in this field.”